Status:
COMPLETED
Effect of Pharmacogenetics on Imatinib Plasma Level and Response
Lead Sponsor:
Assiut University
Conditions:
Chronic Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
Imatinib, the tyrosine kinase inhibitor, is used for treatment of Philadelphia positive chronic myeloid leukemia. Despite its efficacy and favorable pharmacokinetic profile, there is a large inter-ind...
Detailed Description
Introduction: Chronic myeloid leukaemia (CML) is a myeloproliferative disease with an incidence of one to two cases per 100,000 adults. It accounts for approximately 15% of newly diagnosed cases of l...
Eligibility Criteria
Inclusion
- Documented hematological, cytogenetic and molecular diagnosis of Philadelphia positive CML
- Imatinib treatment for at least 12 months
Exclusion
- Poor compliance to treatment
- identification of gene mutation(s) in the kinase domain of BCR- ABL1.
Key Trial Info
Start Date :
October 29 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03262974
Start Date
October 29 2017
End Date
October 1 2023
Last Update
October 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
South Egypt Cancer Institute
Asyut, Egypt